Vyleesi While Traveling: What You Need to Know About Bremelanotide on the Road
HealthRX.com
Vyleesi is taken as needed, so time zones do not change dosing
Key numbers
- 1.75 mgLabel dose per use, given under the skin at least 45 minutes before sex and no more than once in 24 hoursSource: dailymed.nlm.nih.gov, as cited Nov 8, 2026
- 45 minutesMinimum lead time before anticipated sexual activity for each as-needed doseSource: dailymed.nlm.nih.gov, as cited Nov 8, 2026
- 40.0%Women on Vyleesi in pooled phase 3 trials who reported nausea, versus 1.3% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 8, 2026
At a glance
- Drug / Bremelanotide 1.75 mg subcutaneous autoinjector (Vyleesi)
- Approved for / Acquired, generalized HSDD in premenopausal women; not for men or postmenopausal women [1]
- Dosing / As needed, at least 45 minutes before sex; not more than one dose in 24 hours, and more than eight doses a month is not recommended [1]
- Time zones / No scheduled dose to shift, so dosing stays as needed [1]
- Nausea / 40.0% versus 1.3% on placebo; 21% after the first dose, about 3% with later doses [1]
- Blood pressure / Maximal rise of 6 mmHg systolic and 3 mmHg diastolic, peak at 2 to 4 hours, usually back to baseline within 12 hours [1]
- Travel interaction / May slow gastric emptying; avoid with oral drugs that depend on threshold levels, for example antibiotics [1]
- Half-life / About 2.7 hours; median time to peak about 1 hour [1]
Does the 45-minute window change in a new time zone?
No. Vyleesi is taken as needed rather than on a clock schedule, so there is no dose to move when the local time changes. The label directs 1.75 mg under the skin of the abdomen or thigh, at least 45 minutes before anticipated sexual activity [1]. It also states that the duration of efficacy after each dose is unknown, and that patients judge the best timing from how they experience the effect on desire and any adverse reactions such as nausea [1].
Blood levels peak at about one hour after a subcutaneous dose, absolute bioavailability is about 100%, and the mean terminal half-life is about 2.7 hours, with a range of 1.9 to 4.0 hours [1].
What people on Reddit report
Accounts from a women's menopause forum about whether the planned timing still holds when plans are interrupted or delayed.
Nothing happened or me 45 mins after taking Vyleesi except for facial flushing! But boy did it kick in within 2 hours and was with me the whole day!Read the source discussion
That's encouraging because anything can happen and 45 minutes turns to an hour and so on and so forth.Read the source discussion
Questions worth asking
Nausea is the side effect that shapes travel days
Nausea is the most common adverse reaction. In the pooled phase 3 trials, 40.0% of women on Vyleesi reported nausea versus 1.3% on placebo, 13% needed an anti-nausea medicine and 8% stopped the trials because of it [1]. Median onset was within one hour of the dose and it lasted about two hours; it was highest after the first dose (21% of patients) and fell to about 3% with later doses [1].
Pretreatment with oral ondansetron did not reduce nausea in a single-dose study of 228 healthy women, and the label says pre-treatment with oral ondansetron is not recommended [1]. Ondansetron taken after Vyleesi or after nausea begins has not been formally studied [1]. The label suggests considering discontinuation for persistent or severe nausea, or starting anti-nausea therapy for patients who are bothered by nausea but want to continue [1].
Blood pressure and heart rate after each dose
Each dose transiently raises blood pressure and lowers heart rate. In clinical studies the maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with a heart rate reduction of up to 5 beats per minute; values usually returned to baseline within 12 hours, and repeated daily dosing 24 hours apart for up to 16 days produced no additive effect [1]. Those are maximal figures, not averages. In a separate open-label ambulatory study of 127 premenopausal women dosed once daily for 8 days, the mean daytime increase was 1.9 mmHg systolic (95% CI 1.0 to 2.7) and 1.7 mmHg diastolic (95% CI 0.9 to 2.4), with a mean heart rate decrease of 0.5 beats per minute [1].
Vyleesi is contraindicated in women with uncontrolled hypertension or known cardiovascular disease, and the label says it is not recommended for patients at high risk of cardiovascular disease; it also says to consider cardiovascular risk and make sure blood pressure is well controlled before starting and periodically during treatment [1].
Alcohol: what the interaction study found
Alcohol was studied directly. In a placebo-controlled, randomized, double-blind crossover study, 24 healthy volunteers (12 men, 12 women) received a single 20 mg intranasal dose of bremelanotide with 0.6 g/kg of ethanol, and alcohol had no effect on bremelanotide's pharmacokinetics [1]. Flushing was more common with bremelanotide plus ethanol than with ethanol alone but similar to bremelanotide alone; headache was more common than with bremelanotide alone but similar to ethanol alone; and abnormal orthostatic blood pressure reductions were comparable to ethanol alone [1]. The intranasal 20 mg dose reaches a mean Cmax about 2.5-fold higher than the approved subcutaneous dose, so the comparison is not exact [1].
Oral medicines that need to work fast or reach a threshold
Vyleesi may slow gastric emptying, which can reduce the rate and extent of absorption of oral medicines taken at the same time [1]. The label instructs patients to avoid Vyleesi with oral drugs that depend on threshold concentrations for efficacy, naming antibiotics as the example [1]. It also says that when a quick onset of an oral medicine such as indomethacin is wanted and its effect is delayed, patients should consider skipping Vyleesi [1]. In clinical pharmacology studies, only oral naltrexone and indomethacin were meaningfully affected [1]. The named interaction is naltrexone: Vyleesi may significantly decrease the systemic exposure of oral naltrexone, and the label says to avoid the combination with naltrexone products intended to treat alcohol or opioid addiction because of the severe consequence of treatment failure [1].
Skin pigmentation and the monthly dose limit
MC1R sits on pigment cells, and binding there leads to melanin expression and increased pigmentation [1]. In the phase 3 trials, focal hyperpigmentation involving the face, gums or breasts was reported by 1% of patients receiving up to 8 doses a month versus none on placebo; in a separate study, 38% of patients developed focal hyperpigmentation after daily dosing for 8 days, and a further 14% after 8 more consecutive days [1]. Risk is higher in patients with darker skin and with daily dosing, resolution was not confirmed in all patients, and the label says to consider discontinuing if hyperpigmentation develops [1]. The label also notes that more frequent dosing increases the risk of focal hyperpigmentation and the length of time each month when blood pressure is raised, and that few patients in the phase 3 program received more than 8 doses a month [1].
Pregnancy and contraception
The label says to use effective contraception while taking Vyleesi and to discontinue it if pregnancy is suspected [1]. In dogs, daily subcutaneous dosing during organogenesis at exposures at least 16 times the maximum recommended human dose by AUC produced fetal harm [1]. This describes the label effective November 13, 2025; on October 22, 2026 FDA approved a labeling supplement updating the pregnancy and specific-populations section, and that new text was not yet posted on DailyMed on October 28, 2026 [2].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Does jet lag change when I take Vyleesi?
Why does the label advise against ondansetron before a dose?
Can I drink alcohol on a trip while using Vyleesi?
Do antibiotics interfere with Vyleesi?
Can I use Vyleesi if my blood pressure is high?
How fast do bremelanotide levels rise and fall?
References
Show all 3 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration. Approval letter for NDA 210557 supplement S-005 (Vyleesi), 2026. FDA approval letter, NDA 210557 S-005
- Reddit participants. Vyleesi, Is 45 Minutes A Hard Line? (r/Menopause). Accessed 2026-11-11.